The Company is a Korea-based company mainly engaged in the production and sale of veterinary drugs. The Company operates its business through two segments. The Sale Business segment is involved in the provision of livestock disease appraisal services, animal drug distribution, and the manufacturing and sale of feed additives. The New Business segment is engaged in research and development of heterologous organisms, virus like particle (VLP) vaccines, and human diagnostic kits. Heterogeneous organ products include heterologous skin, xenogeneic islets and xenogeneic corneal products, among others. VLP vaccines include VLP based animal combined vaccines and human papillomavirus (HPV) vaccines for the human body, among others. Human body diagnostic kits include human breast cancer and cervical cancer diagnostic reagents, among others. The Company distributes its products within the domestic market and to overseas markets. The Company was established on July 27, 2000. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on October 26, 2018.
Headquarters
63, Oseongsaengmyeong 6-Ro, Osong-Eup, Heungdeok-Gu, Cheongju-Si, Chungcheongbuk-Do
Cheongju; Chungcheongbuk;
Contact Details: Purchase the Optipharm Co.,Ltd report to view the information.
Website: http://www.optipharm.co.kr
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service